Catalyst Dossier · compiled by CeliA 🧫

ADMA BIOLOGICS, INC. (ADMA)

Biological Products, (No Diagnostic Substances) · market cap $1.9B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

ADMA Biologics (ADMA) is a commercial-stage biologics company focused on plasma-derived immunoglobulin therapies, primarily for Primary Immune Deficiency Disorders (PIDD). The company has achieved a sharp revenue inflection — from $81M in 2021 to $510M in 2025 — and is now profitable, with its lead marketed product RI-002 and Nabi-IGIV 10% both in Phase 3 for PIDD. The next near-term catalyst is an earnings print on 2026-08-05.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
RI-002	Phase 3	Primary Immune Deficiency Disorder
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]	Phase 3	Primary Immune Deficiency Disorders (PIDD)
RI-001	Phase 2	Upper Respiratory Tract Infection

Price & technical context

3-month

-4.4%

6-month

-54.9%

12-month

-52.7%

52-wk range

$7.60–$20.38

vs 50-day MA

-2.9%

vs 200-day MA

-38.5%

Realized vol

55.6%

Max drawdown

-69.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ADMA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.